Skip to main content

Research Repository

Advanced Search

Outputs (143)

Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs) (2018)
Presentation / Conference
Hulme, C., Wilson, E., Fuller, H., Roberts, S., Richardson, J., Gallacher, P., …Wright, K. (2018, July). Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs). Poster presented at Matrix Biology Europe – July 2018 Meeting Celebrating 50 years of Federation of European Connective Tissue Societies Meetings, Manchester, United Kingdom

Introduction: Autologous chondrocyte implantation (ACI) is a cell therapy used to treat cartilage defects and early osteoarthritis. During initial surgery (Stage I), healthy cartilage is harvested from the joint. Chondrocytes are isolated and culture... Read More about Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs).

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., …Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

The Royal Stoke University Hospital Pin Site Care Protocol (2018)
Presentation / Conference
McBride, A., & Ogrodnik, P. (2018, May). The Royal Stoke University Hospital Pin Site Care Protocol. Poster presented at EWMA 2018 - European Wound Management Association Annual Conference, Krakow, Poland

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., …Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Paper presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.

An evaluation of the impact of paliperidone and aripiprazole long acting injections on hospital admissions and occupied bed days (2018)
Presentation / Conference
Campbell, A., Awoniyi, O., Aslett, N., Azar, M., Gunnell, K., White, S., …Wing Yee, W. (2018, January). An evaluation of the impact of paliperidone and aripiprazole long acting injections on hospital admissions and occupied bed days. Presented at Prescribing and Research in Medicines Management (UK & Ireland), Annual Conference 2018, National Council for Voluntary Organisations, London

Conference abstract.

An evaluation of paracetamol and ibuprofen prescribing at three high-spend GP practices in Sandwell and West Birmingham: A prescribing analysis study (2018)
Presentation / Conference
Clayton, R., Vadher, N., White, S., & Chapman, S. (2018, January). An evaluation of paracetamol and ibuprofen prescribing at three high-spend GP practices in Sandwell and West Birmingham: A prescribing analysis study. Presented at ANNUAL CONFERENCE 2018, NATIONAL COUNCIL FOR VOLUNTARY ORGANISATIONS, LONDON, UK

Background Paracetamol and ibuprofen are readily available without prescription for relief of pain and pyrexia caused by minor, self-limiting conditions. This study was part of Sandwell and West Birmingham Clinical Commissioning Group’s approach to... Read More about An evaluation of paracetamol and ibuprofen prescribing at three high-spend GP practices in Sandwell and West Birmingham: A prescribing analysis study.

Evaluation of a pharmacist-led diabetes educational outreach programme (2018)
Presentation / Conference
Hin Lai, U., Patel, B., White, S., & Chapman, S. (2018, January). Evaluation of a pharmacist-led diabetes educational outreach programme. Presented at Prescribing and Research in Medicines Management (UK & Ireland), Annual Conference 2018, National Council for Voluntary Organisations, London

Background Independent Monitoring of Prescribing Analysis Cost Trends (IMPACT) campaigns, also known as educational outreach programmes, involve pharmacists providing training programmes in GP surgeries on prescribing for particular clinical issues... Read More about Evaluation of a pharmacist-led diabetes educational outreach programme.

Evaluation of a pharmacist-led telephone triage service in a GP Practice (2017)
Presentation / Conference
Kit Yan, C., White, S., Patel, B., & Chapman, S. (2017, December). Evaluation of a pharmacist-led telephone triage service in a GP Practice. Poster presented at Royal Pharmaceutical Society (RPS) Winter Summit 2017, London, UK

Poster abstract from Conference; Royal Pharmaceutical Society Winter Summit 2017.

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer (2017)
Presentation / Conference
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortes Castan, J. (2017, December). MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Paper presented at 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas

Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endoc... Read More about MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.